MT1013

DRUG4 trials

Sponsors

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Conditions

Healthy VolunteerSecondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on HemodialysisSecondary Hyperparathyroidism, Chronic Kidney Disease

Phase 1

MT1013 Clinical TRIAL In Healthy Subject

CompletedNCT04783090

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Healthy Volunteer

Start: 2021-06-28End: 2022-03-17Updated: 2022-07-29

Phase 2

MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease

CompletedNCT06690242

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Start: 2024-11-04End: 2025-08-30Updated: 2026-07-22

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

RecruitingNCT06976177

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Start: 2024-06-07End: 2025-12-12Target: 310Updated: 2025-05-16

Phase 3

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

RecruitingNCT07122401

Shaanxi Micot Pharmaceutical Technology Co., Ltd.Secondary Hyperparathyroidism, Chronic Kidney Disease

Start: 2025-09-30End: 2026-11-26Target: 424Updated: 2025-10-01